Puma Biotechnology Inc
Closed
SectorHealthcare
6.8 -2.58
Overview
Share price change
24h
Min
6.77
Max
7.03
Income | -16M -3.8M |
|---|---|
Sales | -31M 45M |
P/E Sector Avg | 14.833 49.888 |
EPS | -0.04 |
Profit margin | -8.375 |
Employees | 179 |
EBITDA | -28M -1.3M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -28.37% downside |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | -21M 362M |
|---|---|
Previous open | 9.38 |
Previous close | 6.8 |
Puma Biotechnology Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Puma Biotechnology Inc Forecast
Price Target
By TipRanks
-28.37% downside
12 Months Forecast
Average 5 USD -28.37%
High 5 USD
Low 5 USD
Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
